<DOC>
	<DOCNO>NCT01445236</DOCNO>
	<brief_summary>Immunosuppressive drug successfully withdraw fraction liver transplant patient . Specific peripheral blood gene expression marker employ select patient high likelihood tolerant . In current study investigator propose conduct pilot non-randomized prospective study gradual wean immunosuppressive drug offer liver recipient exhibit favorable peripheral blood gene expression profile .</brief_summary>
	<brief_title>Pilot Study Immunosuppression Drug Weaning Liver Recipients Exhibiting Biomarkers High Likelihood Tolerance</brief_title>
	<detailed_description>HYPOTHESIS We hypothesize liver recipient exhibit either specific gene expression and/or cell phenotypic marker peripheral blood successfully wean immunosuppressive drug . OBJECTIVE Evaluate applicability set non-invasive biomarkers identification liver transplant recipient successfully discontinue immunosuppressive therapy . METODOLOGY 1 . Immunosuppression drug weaning : accord clinical protocol approve , patient undergo liver biopsy entry . Patients visit every 4 week , immunosuppressive drug gradually discontinue aim achieve 50 % decrease drug dosage month 3 , complete withdrawal month 6 initiation study . Following drug discontinuation , patient continue follow every month month 12 initiation study . Liver function test obtain every clinical follow-up visit . 2 . Management liver function test alteration : ) Increases liver function test 2-fold normal level AST/ALT/GGT 1.5-fold normal level ALP result decrease drug dosage , performance new liver function test 14 day . Worsening persistence liver function test alteration constitute indication liver biopsy . b ) Increases liver function test beyond 2-fold normal level AST/ALT/GGT or1.5-fold normal level ALP . 3 . Diagnosis liver graft rejection : base find 2 3 follow histological criterion : portal inflammation , injury bile duct epithelium , endothelitis . The finding mixed portal/loblular lymphocytic infiltrate attributable cause respond increase immunosuppressive drug dos also consider rejection . 4 . Management rejection episode : patient present mild moderate acute rejection treat 20 mg prednisone decrease dos within 4 6 week . Patients severe acute rejection admit hospital treat high dose IV prednisone ( 500-1000mg/day ) 3 day thereafter oral prednisone decrease dose accord evolution liver function test . In every case patient return previous immunosuppressive dose enough maintain normal near normal liver function test . SAMPLE SIZE According data , success rate immunosuppression withdrawal strategy stable liver transplant recipient transplant 3 year 42 % ( patient consider operationally tolerants ) . Our hypothesis use biomarkers identify potential tolerant patient investigator able increase success rate strategy 78 % . In order achieve success rate sample size need study 25 patient ( power 80 % significance 95 % ) .</detailed_description>
	<criteria>1 . Liver transplant recipient least 3 year postoperative followup gene expression pattern change nontolerant tolerant sirolimus treatment . 2 . Feasibility perform frequent ( every 23 week ) clinical followup visit . 3 . No history graft rejection previous 12 month . 4 . Basal liver biopsy without sign rejection 5 . Stability liver graft function , define : ) normal liver function test ( AST , ALT , ALP , GGT ) least 6 month ; alternatively b ) minor alteration liver function test change previous 6 month ( AST/ALT &lt; 2 fold normal level ; ALP &lt; 1.5 fold normal level ; GGT &lt; 2 fold normal level ; bilirubin &lt; 2 mg/dL ) . 6 . Presence peripheral blood biomarkers high likelihood tolerance define : ) transcriptional pattern associate tolerance regardless basal immunosuppressive regimen ; and/or b ) 2fold increase Treg frequency patient discontinue calcineurin inhibitor 12 month prior inclusion . 7 . Signature informed consent . 1 . Requirement immunosuppressive treatment indication different liver transplantation . 2 . Documented human immunodeficiency virus ( HIV ) infection . 3 . LiverKidney transplant recipient . 4 . History liver autoimmune disease ( autoimmune hepatitis , primary liver cirrhosis , primary sclerosing cholangitis ) 5 . Active hepatitis C virus infection define positive serum HCVRNA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Operational tolerance</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Liver Transplantation</keyword>
</DOC>